Evoke Pharma (EVOK) Stock Forecast, Price Target & Predictions
EVOK Stock Forecast
Evoke Pharma stock forecast is as follows: an average price target of $18.00 (represents a 214.69% upside from EVOK’s last price of $5.72) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
EVOK Price Target
The average price target for Evoke Pharma (EVOK) is $18.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $18.00. This represents a potential 214.69% upside from EVOK's last price of $5.72.
EVOK Analyst Ratings
According to 1 Wall Street analysts, Evoke Pharma's rating consensus is 'Buy'. The analyst rating breakdown for EVOK stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Evoke Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 28, 2024 | Yale Jen | Laidlaw | $18.00 | $7.08 | 154.24% | 214.69% |
The latest Evoke Pharma stock forecast, released on Oct 28, 2024 by Yale Jen from Laidlaw, set a price target of $18.00, which represents a 154.24% increase from the stock price at the time of the forecast ($7.08), and a 214.69% increase from EVOK last price ($5.72).
Evoke Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $18.00 | $18.00 | $18.00 |
| Last Closing Price | $5.72 | $5.72 | $5.72 |
| Upside/Downside | 214.69% | 214.69% | 214.69% |
In the current month, the average price target of Evoke Pharma stock is $18.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 214.69% increase as opposed to Evoke Pharma's last price of $5.72. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | Laidlaw | Buy | Buy | Hold |
Evoke Pharma's last stock rating was published by Laidlaw on Oct 28, 2024. The company gave EVOK a "Buy" rating, the same as its previous rate.
Evoke Pharma Financial Forecast
Evoke Pharma Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $1.68M | $1.56M | $1.13M | $810.41K | $796.37K | $832.10K | $461.80K | $418.38K | $360.57K | $930.45K | $236.63K | $90.42K | $23.02K |
| Avg Forecast | $3.74M | $3.36M | $2.98M | $2.14M | $1.63M | $1.26M | $1.10M | $1.00M | $889.00K | $572.00K | $580.00K | $535.00K | $507.00K | $382.00K | $151.00K | $266.00K | $845.00K |
| High Forecast | $3.74M | $3.36M | $2.98M | $2.14M | $1.63M | $1.26M | $1.10M | $1.00M | $889.00K | $572.00K | $580.00K | $535.00K | $507.00K | $382.00K | $151.00K | $266.00K | $845.00K |
| Low Forecast | $3.74M | $3.36M | $2.98M | $2.14M | $1.63M | $1.26M | $1.10M | $1.00M | $889.00K | $572.00K | $580.00K | $535.00K | $507.00K | $382.00K | $151.00K | $266.00K | $845.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | 1.03% | 1.24% | 1.03% | 0.81% | 0.90% | 1.45% | 0.80% | 0.78% | 0.71% | 2.44% | 1.57% | 0.34% | 0.03% |
Evoke Pharma's average Quarter revenue forecast for Mar 24 based on 1 analysts is $2.14M, with a low forecast of $2.14M, and a high forecast of $2.14M. EVOK's average Quarter revenue forecast represents a 27.57% increase compared to the company's last Quarter revenue of $1.68M (Dec 23).
Evoke Pharma EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | $-1.89M | $-1.60M | $-1.78M | $-2.12M | $-1.68M | $-1.89M | $-2.11M | $-2.05M | $-1.55M | $-1.84M | $-2.17M | $-2.48M | $-2.21M |
| Avg Forecast | $-2.24M | $-2.01M | $-1.79M | $-1.28M | $-979.20K | $-757.80K | $-657.60K | $-601.80K | $-533.40K | $-343.20K | $-348.00K | $-1.89M | $-304.20K | $-229.20K | $-90.60K | $-1.65M | $-507.00K |
| High Forecast | $-2.24M | $-2.01M | $-1.79M | $-1.28M | $-979.20K | $-757.80K | $-657.60K | $-601.80K | $-533.40K | $-343.20K | $-348.00K | $-1.51M | $-304.20K | $-229.20K | $-90.60K | $-1.32M | $-507.00K |
| Low Forecast | $-2.24M | $-2.01M | $-1.79M | $-1.28M | $-979.20K | $-757.80K | $-657.60K | $-601.80K | $-533.40K | $-343.20K | $-348.00K | $-2.27M | $-304.20K | $-229.20K | $-90.60K | $-1.99M | $-507.00K |
| Surprise % | - | - | - | - | 1.93% | 2.12% | 2.71% | 3.52% | 3.14% | 5.50% | 6.06% | 1.08% | 5.08% | 8.04% | 23.91% | 1.50% | 4.36% |
undefined analysts predict EVOK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Evoke Pharma's previous annual EBITDA (undefined) of $NaN.
Evoke Pharma Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | $-1.99M | $-1.69M | $-1.87M | $-2.45M | $-1.77M | $-1.99M | $-2.23M | $-2.17M | $-1.67M | $-1.97M | $-2.29M | $-2.61M | $-2.27M |
| Avg Forecast | $-340.88K | $-518.14K | $-981.74K | $-3.44M | $-8.18M | $-10.14M | $-11.94M | $-9.49M | $-8.67M | $-10.80M | $-9.82M | $-2.01M | $-15.71M | $-13.74M | $-15.71M | $-1.74M | $-26.51M |
| High Forecast | $-340.88K | $-518.14K | $-981.74K | $-3.44M | $-8.18M | $-10.14M | $-11.94M | $-9.49M | $-8.67M | $-10.80M | $-9.82M | $-1.60M | $-15.71M | $-13.74M | $-15.71M | $-1.39M | $-26.51M |
| Low Forecast | $-340.88K | $-518.14K | $-981.74K | $-3.44M | $-8.18M | $-10.14M | $-11.94M | $-9.49M | $-8.67M | $-10.80M | $-9.82M | $-2.41M | $-15.71M | $-13.74M | $-15.71M | $-2.08M | $-26.51M |
| Surprise % | - | - | - | - | 0.24% | 0.17% | 0.16% | 0.26% | 0.20% | 0.18% | 0.23% | 1.08% | 0.11% | 0.14% | 0.15% | 1.50% | 0.09% |
Evoke Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. EVOK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Evoke Pharma SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | $3.48M | $3.13M | $2.77M | $2.85M | $2.29M | $2.61M | $2.32M | $2.41M | $1.74M | $2.64M | $2.14M | $2.34M | $2.04M |
| Avg Forecast | $218.25M | $196.07M | $174.00M | $124.83M | $95.29M | $73.74M | $63.99M | $58.56M | $51.91M | $33.40M | $33.86M | $31.24M | $29.60M | $22.30M | $8.82M | $15.53M | $49.34M |
| High Forecast | $218.25M | $196.07M | $174.00M | $124.83M | $95.29M | $73.74M | $63.99M | $58.56M | $51.91M | $33.40M | $33.86M | $31.24M | $29.60M | $22.30M | $8.82M | $15.53M | $49.34M |
| Low Forecast | $218.25M | $196.07M | $174.00M | $124.83M | $95.29M | $73.74M | $63.99M | $58.56M | $51.91M | $33.40M | $33.86M | $31.24M | $29.60M | $22.30M | $8.82M | $15.53M | $49.34M |
| Surprise % | - | - | - | - | 0.04% | 0.04% | 0.04% | 0.05% | 0.04% | 0.08% | 0.07% | 0.08% | 0.06% | 0.12% | 0.24% | 0.15% | 0.04% |
Evoke Pharma's average Quarter SG&A projection for Mar 24 is $124.83M, based on 1 Wall Street analysts, with a range of $124.83M to $124.83M. The forecast indicates a 3484.75% rise compared to EVOK last annual SG&A of $3.48M (Dec 23).
Evoke Pharma EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | $-0.59 | $-0.51 | $-0.56 | $-0.73 | $-0.56 | $-0.60 | $-0.71 | $-0.80 | $-0.62 | $-0.72 | $-0.84 | $-0.96 | $-0.09 |
| Avg Forecast | $-0.25 | $-0.38 | $-0.72 | $-2.52 | $-6.00 | $-7.44 | $-8.76 | $-6.96 | $-6.36 | $-7.92 | $-7.20 | $-5.76 | $-11.52 | $-10.08 | $-11.52 | $-10.08 | $-19.44 |
| High Forecast | $-0.25 | $-0.38 | $-0.72 | $-2.52 | $-6.00 | $-7.44 | $-8.76 | $-6.96 | $-6.36 | $-7.92 | $-7.20 | $-5.76 | $-11.52 | $-10.08 | $-11.52 | $-10.08 | $-19.44 |
| Low Forecast | $-0.25 | $-0.38 | $-0.72 | $-2.52 | $-6.00 | $-7.44 | $-8.76 | $-6.96 | $-6.36 | $-7.92 | $-7.20 | $-5.76 | $-11.52 | $-10.08 | $-11.52 | $-10.08 | $-19.44 |
| Surprise % | - | - | - | - | 0.10% | 0.07% | 0.06% | 0.10% | 0.09% | 0.08% | 0.10% | 0.14% | 0.05% | 0.07% | 0.07% | 0.10% | 0.00% |
According to undefined Wall Street analysts, Evoke Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to EVOK previous annual EPS of $NaN (undefined).
Evoke Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $1.78 | $10.00 | 461.80% | - |
| EVOK | Evoke Pharma | $5.72 | $18.00 | 214.69% | Buy |
| AQST | Aquestive Therapeutics | $5.15 | $9.50 | 84.47% | Buy |
| AVDL | Avadel Pharmaceuticals | $14.86 | $17.80 | 19.78% | Buy |
| AGRX | Agile Therapeutics | $1.51 | $1.00 | -33.77% | Buy |
| GHSI | Guardion Health Sciences | $3.22 | $0.01 | -99.69% | Buy |
EVOK Forecast FAQ
Is Evoke Pharma a good buy?
Yes, according to 1 Wall Street analysts, Evoke Pharma (EVOK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of EVOK's total ratings.
What is EVOK's price target?
Evoke Pharma (EVOK) average price target is $18 with a range of $18 to $18, implying a 214.69% from its last price of $5.72. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Evoke Pharma stock go up soon?
According to Wall Street analysts' prediction for EVOK stock, the company can go up by 214.69% (from the last price of $5.72 to the average price target of $18), up by 214.69% based on the highest stock price target, and up by 214.69% based on the lowest stock price target.
Can Evoke Pharma stock reach $9?
EVOK's average twelve months analyst stock price target of $18 supports the claim that Evoke Pharma can reach $9 in the near future.
What is Evoke Pharma's current price target trend?
1 Wall Street analyst forecast a $18 price target for Evoke Pharma (EVOK) this month, up 214.69% from its last price of $5.72. Compared to the last 3 and 12 months, the average price target increased by 214.69% and increased by 214.69%, respectively.
What are Evoke Pharma's analysts' financial forecasts?
EVOK's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $12.21M (high $12.21M, low $12.21M), average EBITDA is $-7.328M (high $-7.328M, low $-7.328M), average net income is $-5.277M (high $-5.277M, low $-5.277M), average SG&A $713.15M (high $713.15M, low $713.15M), and average EPS is $-3.87 (high $-3.87, low $-3.87).
Did the EVOK's actual financial results beat the analysts' financial forecasts?
Based on Evoke Pharma's last annual report (Dec 2023), the company's revenue was $5.18M, beating the average analysts forecast of $4.99M by 3.74%. Apple's EBITDA was $-7.431M, beating the average prediction of $-2.996M by 147.99%. The company's net income was $-7.792M, missing the average estimation of $-39.761M by -80.40%. Apple's SG&A was $12.23M, missing the average forecast of $291.59M by -95.81%. Lastly, the company's EPS was $-2.33, missing the average prediction of $-29.16 by -92.01%. In terms of the last quarterly report (Dec 2023), Evoke Pharma's revenue was $1.68M, beating the average analysts' forecast of $1.63M by 2.70%. The company's EBITDA was $-1.888M, beating the average prediction of $-979K by 92.80%. Evoke Pharma's net income was $-1.987M, missing the average estimation of $-8.181M by -75.71%. The company's SG&A was $3.48M, missing the average forecast of $95.29M by -96.35%. Lastly, the company's EPS was $-0.59, missing the average prediction of $-6 by -90.17%